Literature DB >> 31020089

Hypertensive crisis during catheter ablation of atrial fibrillation in a patient with undiagnosed pheochromocytoma: a case report.

Kentaro Yoshida1,2, Kazuhiro Iijima3, Ikuo Yoshida1,4, Tatsuhide Hiramine5,6.   

Abstract

INTRODUCTION: Pheochromocytoma is an unusual cause of hypertension accounting for 0.1% of cases. As the development of atrial fibrillation (AF) is tightly associated with hypertension, patients with pheochromocytoma are at higher risk for AF. CASE
PRESENTATION: A 72-year-old woman with undiagnosed pheochromocytoma underwent catheter ablation of drug-resistant AF. Procedure-related external factors, such as prescription of a beta blocker without the preventive administration of an alpha blocker, use of contrast medium, administration of anaesthetics, and emotional and pain-related stress, caused a hypertensive crisis with acute left ventricular dysfunction during ablation procedure. After surgical resection of the adrenal tumour, sinus rhythm was maintained without antiarrhythmic drugs. DISCUSSION: Because hypertensive crisis can lead to life-threatening organ damage, electrophysiologists seeing patients with AF should always consider pheochromocytoma as a mechanism of hypertension and AF before proceeding to catheter ablation of the AF.

Entities:  

Keywords:  Atrial fibrillation; Case report; Catheter ablation; Hypertensive crisis; Pheochromocytoma

Year:  2018        PMID: 31020089      PMCID: PMC6426115          DOI: 10.1093/ehjcr/yty007

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Learning points The prevalence of secondary hypertension is reported to be 5–10% among hypertensive patients. Patients with secondary hypertension show a highly significant 7- to 12-fold increased risk of atrial fibrillation (AF) when compared with patients with essential hypertension. Patients who undergo catheter ablation of AF are at higher risk of periprocedural hypertensive crisis if pheochromocytoma is underdiagnosed. Electrophysiologists seeing patients with AF should consider phechromocytoma as a mechanism of drug-resistant AF before proceeding to catheter ablation.

Introduction

Pheochromocytoma is a catecholamine-producing neoplasm arising from chromaffin cells and is an unusual cause of hypertension accounting for at most 0.1–0.2% of cases. Because of paroxysmal elevation of the blood pressure and the lack of symptoms in these patients, 50% of pheochromocytomas are not diagnosed until autopsy., As the development of atrial fibrillation (AF) is tightly associated with hypertension and resultant atrial stretch, patients with pheochromocytoma are at higher risk for AF. Particularly in patients undergoing catheter ablation of AF, the periprocedural prescription of beta blockers without the preventive administration of an alpha blocker, use of contrast medium, administration of anaesthetics during the procedure, and emotional and pain-related stress associated with invasive procedures are common. Because these external factors can all be causes of a hypertensive crisis associated with pheochromocytoma, patients with undiagnosed pheochromocytoma may be highly susceptible to such crisis during the periprocedural period of catheter ablation of AF.

Timeline

Case presentation

A 72-year-old woman was referred for catheter ablation of persistent AF. Her chief complaint was mild dyspnoea and palpitations on effort. She had a history of hypertension for 5 years without anti-hypertensive drugs and AF for 12 months. Atrial fibrillation had persisted continuously for 5 months. Cardiac auscultation revealed increased intensity of the second heart sound (S2) but no murmurs or gallops. The remainder of the physical examination was unremarkable. A12-lead electrocardiogram (ECG) showed AF with negative T waves in leads I, aVL, and V3 to V6 (Figure A). An echocardiogram revealed normal left ventricular (LV) function with an ejection fraction of 66% and an enlarged left atrium (LA) with a volume of 80 mL. Her blood pressure at the outpatient clinic was 151/80 mmHg, and the beta blocker bisoprolol 2.5 mg was newly prescribed for rate control. A pre-procedural ECG-gated computed tomography (CT) scan using non-ionic contrast medium was performed without adverse events 1 week before catheter ablation to assess the left atrial and pulmonary venous anatomy.
Figure 1

Twelve-lead electrocardiogram of the atrial tachyarrhythmias. (A) Atrial fibrillation before ablation and (B) atrial tachycardia that occurred after ablation. Red arrows indicate discrete P waves in lead V1 (cycle length = 300 ms).

Twelve-lead electrocardiogram of the atrial tachyarrhythmias. (A) Atrial fibrillation before ablation and (B) atrial tachycardia that occurred after ablation. Red arrows indicate discrete P waves in lead V1 (cycle length = 300 ms). Catheter ablation was performed with conscious sedation using dexmedetomidine (0.7 mcg/kg/h) and fentanyl (20 mcg/kg/h). Throughout the procedure, arterial pressure was invasively measured using a 4 Fr sheath inserted in the femoral artery. After coronary angiography and pulmonary venography, antral pulmonary vein isolation was performed under the guidance of a three-dimensional electro-anatomical mapping system (CARTO, Biosense Webster, Diamond Bar, CA, USA). Although her blood pressure at presentation to the laboratory was 120/76 mmHg and the sedation was appropriate with a Ramsay sedation score of 4–5, her systolic blood pressure began to dramatically fluctuate within a range of 80–255 mmHg (Figure ). The intravenous injection of nicardipine 0.5 mg was repeated, but its effect was transient, and the BP remained totally uncontrolled. Particularly after the direct cardioversion of AF, her blood pressure was markedly elevated despite the administration of thiamylal sodium 100 mg. This situation fulfilled the definition of a hypertensive crisis. A low-voltage area suggesting advanced structural remodelling was broadly observed in the LA, and pulmonary vein isolation was followed by linear ablation at the mitral isthmus and superior vena cava isolation (Figure ). Although the procedure was completed without complications, the LV ejection fraction after ablation was significantly decreased to 48% compared with 66% before ablation. Blood pressure measurements and CARTO map during the catheter ablation procedure. (A) Uncontrolled blood pressure and hypertensive crisis. (B) Electroanatomical voltage map. The low-voltage area was defined as a voltage of <0.5 mV. CAG, coronary angiography; DC, direct cardioversion; i.v., intravenous; LA, left atrium; LIPV, left inferior pulmonary vein; MV, mitral valve; PVG, pulmonary venography; RA, right atrium; SVC, superior vena cava. Abdominal magnetic resonance imaging and 123I-metaiodobenzylguanidine scintigraphy. (A) The white arrow indicates the enhanced (A2 phase) right adrenal tumour. (B) High accumulation of 123I-metaiodobenzylguanidine observed in the tumour is consistent with pheochromocytoma. We speculated the presence of secondary hypertension, and her serum catecholamine levels measured 4 weeks after ablation were found to be clearly elevated [adrenalin 0.03 ng/mL (normal range = 0.00–0.10 ng/mL), noradrenalin 3.36 ng/mL (0.10–0.50 ng/mL), and dopamine <0.01 ng/mL (0.00–0.03 ng/mL)]. A 24-hour urine test revealed a normal level of metanephrines of 0.11 mg/day (0.04–0.18) but an increased level of normetanephrine of 1.40 mg/day (0.10–0.28). An enhanced magnetic resonance imaging showed a 2.8-cm right-sided adrenal mass, and 123I-metaiodobenzylguanidine scintigraphy showed high accumulation in association with the tumour (Figure ). Pheochromocytoma was highly suspected and doxazosin 2 mg was immediately prescribed. To stabilize her blood pressure and increase the circulating plasma volume, additional phased prescriptions of doxazosin 16 mg, prazosin 6 mg, propranolol 30 mg, and nifedipine 80 mg were required. Finally, surgery was performed 11 months after the ablation, and an adrenal mass consistent with pheochromocytoma was successfully resected. Although a slow AT with an atrial cycle length of 300 ms was observed after ablation (Figure ), it never recurred after postoperative stabilization of the blood pressure. Her serum noradrenalin and urine normetanephrine levels returned to values within normal limits. During a follow-up period of 35 months, the patient has remained free of any episodes of AF or AT without the need for antiarrhythmic drugs, and her LV function has completely normalized.

Discussion

It is well known that 50–90% of patients with AF have hypertension., The prevalence of secondary hypertension was reported to be 5–10% among hypertensive patients. Because patients with primary aldosteronism showed a highly significant 7- to 12-fold increased risk of AF when compared with patients with essential hypertension,, electrophysiologists performing catheter ablation of AF may have more opportunities to encounter patients with secondary hypertension. Pheochromocytoma is also an important form of secondary hypertension because under-diagnosis can lead to life-threatening organ damage. Catecholamine-induced cardiac remodelling and atrial stretch may facilitate the occurrence and persistence of atrial tachyarrhythmias, and therefore, curing the pheochromocytoma may critically contribute to the restoration of sinus rhythm, similarly to treatment for primary aldosteronism. Unfortunately, pheochromocytoma was undiagnosed in the present patient until ablation therapy was performed and the following risks for hypertensive crisis were recognized. (i) A beta- blocker was prescribed without the preventive administration of an alpha-adrenoceptor blocking agent. The unopposed stimulation of alpha-adrenoceptors could lead to a rise in blood pressure. (ii) A contrast-enhanced CT scan, coronary angiography, and pulmonary venography were performed without administration of alpha-adrenergic blockade. Although small studies recently reported that non-ionic low osmolar contrast medium had no appreciable effect on catecholamine release in patients with pheochromocytoma, there is still one case report showing the occurrence of hypertensive crisis due to a contrast-enhanced CT scan. (iii) During the procedure, alpha-2 adrenoceptor agonist dexmedetomidine was used for sedation and mild analgesia in combination with fentanyl. Although there are few vascular effects from the activation of alpha-1 receptors during low-dose infusion, higher concentrations of dexmedetomidine cause a biphasic (low, then high) dose–response relation of blood pressure and vascular resistances, which results in systemic hypertension. (iv) The patient was potentially dehydrated due to fasting and experienced emotional and pain-related stress during the periprocedural period. As a result, the patient suffered from hypertensive crisis (systolic pressure >180 and diastolic pressure >120 mmHg, and the acute presentation of LV dysfunction). The decrease in the ejection fraction may be explained by the increased LV afterload and catecholamine-mediated myocarditis. It was also noteworthy that a recurrent AT resolved with no need for anti-arrhythmic drugs during long-term follow-up after cure of the pheochromocytoma by surgical resection. Although it is unclear if AF can be treated only with surgical resection of the tumour and normalization of catecholamine levels, we believe that the maintenance of sinus rhythm by catheter ablation is difficult to achieve without resolution of the pheochromocytoma. The present results suggest that electrophysiologists seeing patients with AF should consider secondary hypertension as a mechanism of hypertension and drug-resistant AF before proceeding to catheter ablation of AF.

Conclusions

Particularly in patients with AF who are scheduled to undergo catheter ablation, under-diagnosis of pheochromocytoma can lead to a lethal hypertensive crisis due to periprocedural medications, imaging studies using contrast medium, anaesthesia, and emotional and pain-related stress. Electrophysiologists should recognize the possibility that they may more frequently encounter patients with secondary hypertension in association with AF in clinical practice.
5 years prior to admissionHypertension was diagnosed at a medical check-up
12 months prior to admissionParoxysmal atrial fibrillation was documented by electrocardiogram
5 months prior to admissionAtrial fibrillation was converted to persistent form
Admission and catheter ablation for atrial fibrillation (0 days)Hypertensive crisis occurred during the procedure
4 weeks after catheter ablationPheochromocytoma was highly suspected based on blood and urine analyses, magnetic resonance imaging, and 123I-metaiodobenzylguanidine scintigraphy
11 months after catheter ablationPhased prescriptions of anti-hypertensive drugs were required to control the blood pressure and to increase the circulating plasma volume. Surgical resection of the tumour was performed
35 months after catheter ablationA 30-day loop recorder did not detect any atrial fibrillation episodes
  10 in total

Review 1.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

2.  CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material.

Authors:  Richard Bessell-Browne; Martin E O'Malley
Journal:  AJR Am J Roentgenol       Date:  2007-04       Impact factor: 3.959

3.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

4.  The effects of increasing plasma concentrations of dexmedetomidine in humans.

Authors:  T J Ebert; J E Hall; J A Barney; T D Uhrich; M D Colinco
Journal:  Anesthesiology       Date:  2000-08       Impact factor: 7.892

5.  Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice.

Authors:  Silvia Monticone; Jacopo Burrello; Davide Tizzani; Chiara Bertello; Andrea Viola; Fabrizio Buffolo; Luisa Gabetti; Giulio Mengozzi; Tracy A Williams; Franco Rabbia; Franco Veglio; Paolo Mulatero
Journal:  J Am Coll Cardiol       Date:  2017-04-11       Impact factor: 24.094

6.  Hypertensive crisis due to contrast-enhanced computed tomography in a patient with malignant pheochromocytoma.

Authors:  Sachiko Nakano; Yoshito Tsushima; Ayako Taketomi-Takahashi; Tetsuya Higuchi; Makoto Amanuma; Noboru Oriuchi; Keigo Endo
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

7.  Atrial fibrillation in hypertension: predictors and outcome.

Authors:  Paolo Verdecchia; GianPaolo Reboldi; Roberto Gattobigio; Maurizio Bentivoglio; Claudia Borgioni; Fabio Angeli; Erberto Carluccio; Maria Grazia Sardone; Carlo Porcellati
Journal:  Hypertension       Date:  2003-02       Impact factor: 10.190

Review 8.  Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features.

Authors:  Alberto Mazza; Michela Armigliato; Maria Cristina Marzola; Laura Schiavon; Domenico Montemurro; Giorgio Vescovo; Marco Zuin; Sotirios Chondrogiannis; Roberta Ravenni; Giuseppe Opocher; Patrick M Colletti; Domenico Rubello
Journal:  Endocrine       Date:  2013-07-02       Impact factor: 3.633

9.  Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.

Authors:  Gian Paolo Rossi; Maurizio Cesari; Cesare Cuspidi; Giuseppe Maiolino; Maria Verena Cicala; Valeria Bisogni; Franco Mantero; Achille C Pessina
Journal:  Hypertension       Date:  2013-05-06       Impact factor: 10.190

10.  Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction.

Authors:  Vanessa M Ferreira; Mafalda Marcelino; Stefan K Piechnik; Claudia Marini; Theodoros D Karamitsos; Ntobeko A B Ntusi; Jane M Francis; Matthew D Robson; J Ranjit Arnold; Radu Mihai; Julia D J Thomas; Maria Herincs; Zaki K Hassan-Smith; Andreas Greiser; Wiebke Arlt; Márta Korbonits; Niki Karavitaki; Ashley B Grossman; John A H Wass; Stefan Neubauer
Journal:  J Am Coll Cardiol       Date:  2016-05-24       Impact factor: 24.094

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.